Health News Archive - May 13, 2010
HAYWARD, Calif., May 13 /PRNewswire-FirstCall/ -- Solta Medical, Inc.
All amounts are in U.S. dollars QUEBEC CITY, May 13 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc.
DUBLIN and PHILADELPHIA, May 13, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that its subsidiary Shire LLC has filed a lawsuit in the U.S. District Court for the District of Delaware against Actavis Elizabeth LLC and Actavis Inc.
HARBIN, China, May 13 /PRNewswire-Asia-FirstCall/ -- SOKO Fitness & Spa Group, Inc.
SALT LAKE CITY, May 13 /PRNewswire-FirstCall/ -- A newly awarded U.S. Patent will protect TechniScan, Inc's., (OTC Bulletin Board: TSNI) novel way to image, biopsy and treat breast cancer. U.S.
WALTHAM, Mass., May 13 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today that it has filed an Investigational New Drug Application (IND) with the Food and Drug Administration (FDA) for a Phase 1 study of RG2833, a selective histone deacetylase 3 (HDAC-3) inhibitor.
MOUNTAIN VIEW, Calif., May 13 /PRNewswire-FirstCall/ -- VIVUS, Inc.
CHAPEL HILL, N.C., May 13 /PRNewswire/ -- Cempra Pharmaceuticals today announced the schedule of poster presentations on its next-generation macrolide, CEM-101, at the American Thoracic Society (ATS) 2010 International Conference in New Orleans, Louisiana, on May 14 to 19, 2010. Both posters will be presented during the poster session entitled "C41 Emerging Pharmacology for Chronic Obstructive Pulmonary Disease: Mechanisms and Outcomes" scheduled for 8:15 a.m.
BRISBANE, Calif., May 13 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that an oral presentation and six posters related to the company's pulmonology programs will be presented at the 2010 International Conference of the American Thoracic Society (ATS) in New Orleans.
The European Medicines Agency (EMEA) said on Wednesday it had been informed of a new regenerative medicine based on stem cells that is looking for approval later this year, bringing the groundbreaking medical technology a step closer to reality.